Fenebrutinib Update. Clinical Trial Results, Liver Disease, and Death

About this video

• Video Title: Fenebrutinib Update. Clinical Trial Results, Liver Disease, and Death
• Channel: Dr. Brandon Beaber
• Speakers: Dr. Brandon Beaber
• Duration: 22:12

Overview

This video provides an update on the investigational multiple sclerosis drug fenebrutinib, discussing results from clinical trials, potential side effects like liver injury, and an observed increase in deaths compared to comparator drugs. Dr. Beaber breaks down the data from trials in relapsing and progressive MS, analyzing efficacy, safety, and comparing it to existing treatments.

Key takeaways

• Fenebrutinib is a Bruton's tyrosine kinase inhibitor being investigated for multiple sclerosis.
• In relapsing MS trials (Fenhance 1 & 2), fenebrutinib showed superiority over the lower efficacy drug Aabagio in reducing relapses, but the absolute benefit was modest.
• In progressive MS trials (Fentrepia), fenebrutinib demonstrated similar efficacy to Ocrevus in slowing disability progression, with a slight trend favoring fenebrutinib, though not statistically significant.
• A significant concern is the observed higher rate of deaths in patients taking fenebrutinib across the trials compared to those taking Ocrevus or Aabagio.
• While liver enzyme elevations occurred more frequently with fenebrutinib, serious drug-induced liver injury was rare in the trial setting, though the risk might be higher in the real world.